A dose ranging study investigating the efficacy and safety of sublingual immunotherapy tablets of house dust mite allergen extracts in adults with house dust mite-associated allergic asthma
Latest Information Update: 07 Nov 2021
At a glance
- Drugs S 524101 (Primary)
- Indications Allergic asthma; Hypersensitivity
- Focus Therapeutic Use
- Sponsors Stallergenes SA
- 07 Mar 2016 Primary endpoint of effect on the asthma control test (ACT) score has not been met, according to results presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 07 Mar 2016 Results presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 17 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.